{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T22:31:04Z","timestamp":1791153064118,"version":"4.1.0"},"reference-count":111,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,9,16]],"date-time":"2012-09-16T00:00:00Z","timestamp":1347753600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1186\/1756-8722-5-55","type":"journal-article","created":{"date-parts":[[2012,9,16]],"date-time":"2012-09-16T06:14:11Z","timestamp":1347776051000},"source":"Crossref","is-referenced-by-count":29,"title":["Therapeutic advancement of chronic lymphocytic leukemia"],"prefix":"10.1186","volume":"5","author":[{"given":"Kang","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,9,16]]},"reference":[{"key":"247_CR1","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1016\/S0140-6736(08)60456-0","volume":"371","author":"G Dighiero","year":"2008","unstructured":"Dighiero G, Hamblin TJ: Chronic lymphocytic leukaemia. Lancet. 2008, 371: 1017-1029. 10.1016\/S0140-6736(08)60456-0.","journal-title":"Lancet"},{"key":"247_CR2","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/nrc2764","volume":"10","author":"T Zenz","year":"2010","unstructured":"Zenz T, Mertens D, Kuppers R, Dohner H, Stilgenbauer S: From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev Cancer. 2010, 10: 37-50.","journal-title":"Nat Rev Cancer"},{"key":"247_CR3","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/1756-8722-2-29","volume":"2","author":"KJ Maddocks","year":"2009","unstructured":"Maddocks KJ, Lin TS: Update in the management of chronic lymphocytic leukemia. J Hematol Oncol. 2009, 2: 29-10.1186\/1756-8722-2-29.","journal-title":"J Hematol Oncol"},{"key":"247_CR4","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1056\/NEJM200012143432402","volume":"343","author":"KR Rai","year":"2000","unstructured":"Rai KR, Peterson BL, Appelbaum FR, Kolitz J, Elias L, Shepherd L, Hines J, Threatte GA, Larson RA, Cheson BD, Schiffer CA: Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med. 2000, 343: 1750-1757. 10.1056\/NEJM200012143432402.","journal-title":"N Engl J Med"},{"key":"247_CR5","doi-asserted-by":"publisher","first-page":"3382","DOI":"10.1182\/blood-2009-02-206185","volume":"114","author":"BF Eichhorst","year":"2009","unstructured":"Eichhorst BF, Busch R, Stilgenbauer S, Stauch M, Bergmann MA, Ritgen M, Kranzhofer N, Rohrberg R, Soling U, Burkhard O: First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. Blood. 2009, 114: 3382-3391. 10.1182\/blood-2009-02-206185.","journal-title":"Blood"},{"key":"247_CR6","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1158\/1078-0432.CCR-07-1061","volume":"14","author":"LM Leoni","year":"2008","unstructured":"Leoni LM, Bailey B, Reifert J, Bendall HH, Zeller RW, Corbeil J, Elliott G, Niemeyer CC: Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res. 2008, 14: 309-317. 10.1158\/1078-0432.CCR-07-1061.","journal-title":"Clin Cancer Res"},{"key":"247_CR7","doi-asserted-by":"publisher","first-page":"4378","DOI":"10.1200\/JCO.2008.20.8389","volume":"27","author":"WU Knauf","year":"2009","unstructured":"Knauf WU, Lissichkov T, Aldaoud A, Liberati A, Loscertales J, Herbrecht R, Juliusson G, Postner G, Gercheva L, Goranov S: Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol. 2009, 27: 4378-4384. 10.1200\/JCO.2008.20.8389.","journal-title":"J Clin Oncol"},{"key":"247_CR8","first-page":"3914","volume":"118","author":"KS Kolibaba","year":"2011","unstructured":"Kolibaba KS, Joshi AD, Sterchele JA, Forsyth M, Alwon E, Beygi H, Kennealey GT: Demographics, Treatment Patterns, Safety, and Real-World Effectiveness in Patients > =70 Years of Age with Chronic Lymphocytic Leukemia Receiving Bendamustine with or without Rituximab. ASH Annual Meeting Abstracts. 2011, 118: 3914-","journal-title":"ASH Annual Meeting Abstracts"},{"key":"247_CR9","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1182\/blood-2005-06-2395","volume":"107","author":"BF Eichhorst","year":"2006","unstructured":"Eichhorst BF, Busch R, Hopfinger G, Pasold R, Hensel M, Steinbrecher C, Siehl S, Jager U, Bergmann M, Stilgenbauer S: Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood. 2006, 107: 885-891.","journal-title":"Blood"},{"key":"247_CR10","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/S0140-6736(07)61125-8","volume":"370","author":"D Catovsky","year":"2007","unstructured":"Catovsky D, Richards S, Matutes E, Oscier D, Dyer MJ, Bezares RF, Pettitt AR, Hamblin T, Milligan DW, Child JA: Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet. 2007, 370: 230-239. 10.1016\/S0140-6736(07)61125-8.","journal-title":"Lancet"},{"key":"247_CR11","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1200\/JCO.2006.08.0762","volume":"25","author":"IW Flinn","year":"2007","unstructured":"Flinn IW, Neuberg DS, Grever MR, Dewald GW, Bennett JM, Paietta EM, Hussein MA, Appelbaum FR, Larson RA, Moore DF, Tallman MS: Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. J Clin Oncol. 2007, 25: 793-798. 10.1200\/JCO.2006.08.0762.","journal-title":"J Clin Oncol"},{"key":"247_CR12","first-page":"112","volume":"2008","author":"S Stilgenbauer","year":"2089","unstructured":"Stilgenbauer S, Eichhorst BF, Busch R, Zenz T, Winkler D, Buhler A, Goede V, Wendtner CM, Lichter P, Emmerich B: Biologic and Clinical Markers for Outcome after Fludarabine (F) or F Plus Cyclophosphamide (FC) - Comprehensive Analysis of the CLL4 Trial of the GCLLSG. ASH Annual Meeting Abstracts. 2089, 2008: 112-","journal-title":"ASH Annual Meeting Abstracts"},{"key":"247_CR13","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1200\/JCO.2009.25.9630","volume":"28","author":"T Robak","year":"2010","unstructured":"Robak T, Jamroziak K, Gora-Tybor J, Stella-Holowiecka B, Konopka L, Ceglarek B, Warzocha K, Seferynska I, Piszcz J, Calbecka M: Comparison of cladribine plus cyclophosphamide with fludarabine plus cyclophosphamide as first-line therapy for chronic lymphocytic leukemia: a phase III randomized study by the Polish Adult Leukemia Group (PALG-CLL3 Study). J Clin Oncol. 2010, 28: 1863-1869. 10.1200\/JCO.2009.25.9630.","journal-title":"J Clin Oncol"},{"key":"247_CR14","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1182\/blood-2005-12-4828","volume":"108","author":"T Robak","year":"2006","unstructured":"Robak T, Blonski JZ, Gora-Tybor J, Jamroziak K, Dwilewicz-Trojaczek J, Tomaszewska A, Konopka L, Ceglarek B, Dmoszynska A, Kowal M: Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: report of a prospective, multicenter, randomized trial of the Polish Adult Leukemia Group (PALG CLL2). Blood. 2006, 108: 473-479. 10.1182\/blood-2005-12-4828.","journal-title":"Blood"},{"key":"247_CR15","first-page":"3915","volume":"118","author":"T Robak","year":"2011","unstructured":"Robak T, Blonski J, Jamroziak K, Calbecka M, Dwilewicz-Trojaczek J, Boguradzki P, Dmoszynska A, Kowal M, Kloczko J, Piszcz J: Cladribine Alone and in Combination with Cyclophosphamide or Cyclophosphamide and Mitoxantrone in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL): Long-Term Follow-up of the the Polish Adult Leukemia Group (PALG CLL2) Study. ASH Annual Meeting Abstracts. 2011, 118: 3915-","journal-title":"ASH Annual Meeting Abstracts"},{"key":"247_CR16","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1182\/blood-2002-04-1258","volume":"101","author":"JC Byrd","year":"2003","unstructured":"Byrd JC, Peterson BL, Morrison VA, Park K, Jacobson R, Hoke E, Vardiman JW, Rai K, Schiffer CA, Larson RA: Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood. 2003, 101: 6-14. 10.1182\/blood-2002-04-1258.","journal-title":"Blood"},{"key":"247_CR17","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1200\/JCO.2010.31.1811","volume":"29","author":"JA Woyach","year":"2011","unstructured":"Woyach JA, Ruppert AS, Heerema NA, Peterson BL, Gribben JG, Morrison VA, Rai KR, Larson RA, Byrd JC: Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712. J Clin Oncol. 2011, 29: 1349-1355. 10.1200\/JCO.2010.31.1811.","journal-title":"J Clin Oncol"},{"key":"247_CR18","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1182\/blood-2006-07-033274","volume":"109","author":"NE Kay","year":"2007","unstructured":"Kay NE, Geyer SM, Call TG, Shanafelt TD, Zent CS, Jelinek DF, Tschumper R, Bone ND, Dewald GW, Lin TS: Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. Blood. 2007, 109: 405-411. 10.1182\/blood-2006-07-033274.","journal-title":"Blood"},{"key":"247_CR19","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1002\/cncr.25028","volume":"116","author":"NE Kay","year":"2010","unstructured":"Kay NE, Wu W, Kabat B, LaPlant B, Lin TS, Byrd JC, Jelinek DF, Grever MR, Zent CS, Call TG, Shanafelt TD: Pentostatin and rituximab therapy for previously untreated patients with B-cell chronic lymphocytic leukemia. Cancer. 2010, 116: 2180-2187.","journal-title":"Cancer"},{"key":"247_CR20","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1007\/s10637-011-9737-y","volume":"30","author":"C Reynolds","year":"2012","unstructured":"Reynolds C, Di Bella N, Lyons RM, Hyman W, Richards DA, Robbins GJ, Vellek M, Boehm KA, Zhan F, Asmar L: A Phase III trial of fludarabine, cyclophosphamide, and rituximab vs. pentostatin, cyclophosphamide, and rituximab in B-cell chronic lymphocytic leukemia. Invest New Drugs. 2012, 30: 1232-1240. 10.1007\/s10637-011-9737-y.","journal-title":"Invest New Drugs"},{"key":"247_CR21","first-page":"3901","volume":"118","author":"WG Wierda","year":"2011","unstructured":"Wierda WG, Balakrishnan K, Ferrajoli A, Kadia T, Cortes JE, O'Brien S, Burger JA, Tambaro FP, Jalayer A, Lerner S: A Phase I\/II Trial of Fludarabine, Bendamustine, and Rituximab (FBR) Chemoimmunotherapy for Previously Treated Patients with CLL. ASH Annual Meeting Abstracts. 2011, 118: 3901-","journal-title":"ASH Annual Meeting Abstracts"},{"key":"247_CR22","first-page":"1615","volume":"118","author":"R Weide","year":"2011","unstructured":"Weide R, Feiten S, Friesenhahn V, Heymanns J, Kleboth K, Thomalla J, van Roye C, Koppler H: Retherapy with Bendamustine-Containing Regimens in Patients with Relapsed\/Refractory CLL and Indolent Lymphomas Achieves High Response Rates. ASH Annual Meeting Abstracts. 2011, 118: 1615-","journal-title":"ASH Annual Meeting Abstracts"},{"key":"247_CR23","first-page":"293","volume":"118","author":"F Bosch","year":"2011","unstructured":"Bosch F, Abrisqueta P, Villamor N, Terol MJ, Gonzalez-Barca E, Gonzalez M, Ferra C, Abella E, Delgado J, Garcia-Marco JA: Rituximab Maintenance In Patients with Chronic Lymphocytic Leukemia (CLL) After Upfront Treatment with Rituximab Plus Fludarabine, Cyclophosphamide, and Mitoxantrone (R-FCM): Final Results of a Multicenter Phase II Trial On Behalf of the Spanish CLL Study Group (GELLC). ASH Annual Meeting Abstracts. 2011, 118: 293-","journal-title":"ASH Annual Meeting Abstracts"},{"key":"247_CR24","first-page":"2860","volume":"118","author":"P Jenke","year":"2011","unstructured":"Jenke P, Eichhorst B, Busch R, Anheier N, Duehrsen U, Duerig J, Dreyling MH, Bergmann M, Goebeler ME, Hurtz HJ: Cyclophosphamide, Adriamycin, Vincristine and Prednisone Plus Rituximab (CHOP-R) in Fludarabine (F) Refractory Chronic Lymphocytic Leukemia (CLL) or CLL with Autoimmune Cytopenia (AIC) or Richter's Transformation (RT): Final Analysis of a Phase II Study of the German CLL Study Group. ASH Annual Meeting Abstracts. 2011, 118: 2860-","journal-title":"ASH Annual Meeting Abstracts"},{"key":"247_CR25","doi-asserted-by":"publisher","first-page":"5616","DOI":"10.1200\/JCO.2007.12.9098","volume":"25","author":"P Hillmen","year":"2007","unstructured":"Hillmen P, Skotnicki AB, Robak T, Jaksic B, Dmoszynska A, Wu J, Sirard C, Mayer J: Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol. 2007, 25: 5616-5623. 10.1200\/JCO.2007.12.9098.","journal-title":"J Clin Oncol"},{"key":"247_CR26","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1111\/j.1365-2141.2011.08965.x","volume":"156","author":"A Cortelezzi","year":"2012","unstructured":"Cortelezzi A, Gritti G, Laurenti L, Cuneo A, Ciolli S, Di Renzo N, Musto P, Mauro FR, Cascavilla N, Falchi L: An Italian retrospective study on the routine clinical use of low-dose alemtuzumab in relapsed\/refractory chronic lymphocytic leukaemia patients. Br J Haematol. 2012, 156: 481-489. 10.1111\/j.1365-2141.2011.08965.x.","journal-title":"Br J Haematol"},{"key":"247_CR27","doi-asserted-by":"publisher","first-page":"424","DOI":"10.3109\/10428194.2011.623258","volume":"53","author":"G Gritti","year":"2012","unstructured":"Gritti G, Reda G, Maura F, Piciocchi A, Baldini L, Molica S, Neri A, Cortelezzi A: Low dose alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia. Leuk Lymphoma. 2012, 53: 424-429. 10.3109\/10428194.2011.623258.","journal-title":"Leuk Lymphoma"},{"key":"247_CR28","first-page":"2854","volume":"118","author":"S Stilgenbauer","year":"2011","unstructured":"Stilgenbauer S, Cymbalista F, Leblond V, Delmer A, Winkler D, Buhler A, Zenz T, Mack S, Busch R, Hinke A: Alemtuzumab Plus Oral Dexamethasone. Followed by Alemtuzumab Maintenance or Allogeneic Transplantation in Ultra High-Risk CLL: Interim Analysis of a Phase II Study of the GCLLSG and fcgcll\/MW. ASH Annual Meeting Abstracts. 2011, 118: 2854-","journal-title":"ASH Annual Meeting Abstracts"},{"key":"247_CR29","first-page":"290","volume":"118","author":"CH Geisler","year":"2011","unstructured":"Geisler CH, van 't Veer MM, van Putten W, Jurlander J, Walewski J, Tjonnfjord G, Itala-Remes M, Kimby E, Kozak T, Polliack A: Immunochemotherapy with Low-Dose Subcutaneous Alemtuzumab (A) Plus Oral Fludarabine and Cyclophosphamide (FC) Is Safe and Induces More and Deeper Complete Remissions in Untreated Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) Than Chemotherapy with FC Alone. An Early Analysis of the Randomized Phase-III HOVON68 CLL Trial. ASH Annual Meeting Abstracts. 2011, 118: 290-","journal-title":"ASH Annual Meeting Abstracts"},{"key":"247_CR30","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1182\/blood-2011-03-341032","volume":"118","author":"XC Badoux","year":"2011","unstructured":"Badoux XC, Keating MJ, Wang X, O'Brien SM, Ferrajoli A, Faderl S, Burger J, Koller C, Lerner S, Kantarjian H, Wierda WG: Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia. Blood. 2011, 118: 2085-2093. 10.1182\/blood-2011-03-341032.","journal-title":"Blood"},{"key":"247_CR31","first-page":"1790","volume":"118","author":"CS Zent","year":"2011","unstructured":"Zent CS, LaPlant BR, Link BK, Call TG, Shanafelt TD, Bowen DA, Kay N, Weiner GJ, Witzig TE: Pentostatin, Alemtuzumab, and Low Dose Rituximab Is Effective Therapy for Relapsed\/Refractory Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma (CLL). ASH Annual Meeting Abstracts. 2011, 118: 1790-","journal-title":"ASH Annual Meeting Abstracts"},{"key":"247_CR32","first-page":"3900","volume":"118","author":"A Delmer","year":"2011","unstructured":"Delmer A, Tournilhac O, Lepretre S, Cazin B, Feugier P, Dreyfus B, Mahe B, Leporrier M, Michallet A-S, Jaccard A: Consolidation Therapy with Subcutaneous Alemtuzumab After Induction Treatment with Oral FC (Fludarabine and Cyclophosphamide) in Previously Untreated Patients Aged 65\u201370 Years with Advanced Stage Chronic Lymphocytic Leukemia (CLL): Final Results of a Phase II Study From the FCGCLL\/WM. ASH Annual Meeting Abstracts. 2011, 118: 3900-","journal-title":"ASH Annual Meeting Abstracts"},{"key":"247_CR33","first-page":"2866","volume":"118","author":"JE Castro","year":"2011","unstructured":"Castro JE, Ariza-Serrano LM, Barajas-Gamboa JS, Diaz-Perez JA, James DF, Ale-Ali A, Kipps TJ: Eradication of Minimal Residual Disease Using Alemtuzumab Consolidation After High-Dose Methyl-Prednisolone Plus Rituximab (HDMP-R) Is Safe, Effective and Induces Long Term Remission in Chronic Lymphocytic Leukemia. ASH Annual Meeting Abstracts. 2011, 118: 2866-","journal-title":"ASH Annual Meeting Abstracts"},{"key":"247_CR34","first-page":"1791","volume":"118","author":"JA Jones","year":"2011","unstructured":"Jones JA, Stark A, Zhao W, Lin TS, Rai KR, Marcucci G, Peterson B, Larson RA, Heerema NA, Byrd JC: Alemtuzumab Consolidation Does Not Improve Outcome for CLL Patients with High Risk Genomic Features on Successive CALGB Trials. ASH Annual Meeting Abstracts. 2011, 118: 1791-","journal-title":"ASH Annual Meeting Abstracts"},{"key":"247_CR35","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1200\/JCO.2009.25.3187","volume":"28","author":"WG Wierda","year":"2010","unstructured":"Wierda WG, Kipps TJ, Mayer J, Stilgenbauer S, Williams CD, Hellmann A, Robak T, Furman RR, Hillmen P, Trneny M: Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol. 2010, 28: 1749-1755. 10.1200\/JCO.2009.25.3187.","journal-title":"J Clin Oncol"},{"key":"247_CR36","first-page":"921","volume":"116","author":"WG Wierda","year":"2010","unstructured":"Wierda WG, Kipps TJ, Mayer J, Robak T, Dyer MJ, Furman RR, Hillmen P, Stilgenbauer S, Williams CD, Trneny M: Final Analysis From the International Trial of Single-Agent Ofatumumab In Patients with Fludarabine-Refractory Chronic Lymphocytic Leukemia. ASH Annual Meeting Abstracts. 2010, 116: 921-","journal-title":"ASH Annual Meeting Abstracts"},{"key":"247_CR37","first-page":"3912","volume":"118","author":"IW Flinn","year":"2011","unstructured":"Flinn IW, Harwin WN, Macias-Perez IM, Tucker PS, Waterhouse DM, Papish SW, Jones JA, Hainsworth JD, Byrd JC: A Phase II Trial of Ofatumumab for Older Patients and Patients Who Refuse Fludarabine-Based Regimens with Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma. ASH Annual Meeting Abstracts. 2011, 118: 3912-","journal-title":"ASH Annual Meeting Abstracts"},{"key":"247_CR38","doi-asserted-by":"publisher","first-page":"6450","DOI":"10.1182\/blood-2010-12-323980","volume":"117","author":"WG Wierda","year":"2011","unstructured":"Wierda WG, Kipps TJ, Durig J, Griskevicius L, Stilgenbauer S, Mayer J, Smolej L, Hess G, Griniute R, Hernandez-Ilizaliturri FJ: Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia. Blood. 2011, 117: 6450-6458. 10.1182\/blood-2010-12-323980.","journal-title":"Blood"},{"key":"247_CR39","first-page":"3898","volume":"118","author":"TD Shanafelt","year":"2011","unstructured":"Shanafelt TD, Lanasa MC, Zent CS, Leis JF, Call TG, LaPlant BR, Tun H, Bowen DA, Jelinek DF, Hanson CA, Kay N: Ofatumumab Based Chemoimmunotherapy (CIT) for Patients with Previously Untreated CLL. ASH Annual Meeting Abstracts. 2011, 118: 3898-","journal-title":"ASH Annual Meeting Abstracts"},{"key":"247_CR40","doi-asserted-by":"publisher","first-page":"4448","DOI":"10.1158\/1078-0432.CCR-06-1463","volume":"13","author":"JC Byrd","year":"2007","unstructured":"Byrd JC, O'Brien S, Flinn IW, Kipps TJ, Weiss M, Rai K, Lin TS, Woodworth J, Wynne D, Reid J: Phase 1 study of lumiliximab with detailed pharmacokinetic and pharmacodynamic measurements in patients with relapsed or refractory chronic lymphocytic leukemia. Clin Cancer Res. 2007, 13: 4448-4455. 10.1158\/1078-0432.CCR-06-1463.","journal-title":"Clin Cancer Res"},{"key":"247_CR41","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1182\/blood-2009-08-237727","volume":"115","author":"JC Byrd","year":"2010","unstructured":"Byrd JC, Kipps TJ, Flinn IW, Castro J, Lin TS, Wierda W, Heerema N, Woodworth J, Hughes S, Tangri S: Phase 1\/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia. Blood. 2010, 115: 489-495. 10.1182\/blood-2009-08-237727.","journal-title":"Blood"},{"key":"247_CR42","doi-asserted-by":"publisher","first-page":"3705","DOI":"10.1182\/blood-2010-04-001230","volume":"116","author":"SM Jaglowski","year":"2010","unstructured":"Jaglowski SM, Alinari L, Lapalombella R, Muthusamy N, Byrd JC: The clinical application of monoclonal antibodies in chronic lymphocytic leukemia. Blood. 2010, 116: 3705-3714. 10.1182\/blood-2010-04-001230.","journal-title":"Blood"},{"key":"247_CR43","first-page":"229","volume":"108","author":"P Umana","year":"2006","unstructured":"Umana P, Moessner E, Bruenker P, Unsin G, Puentener U, Suter T, Grau R, Schmidt C, Gerdes C, Nopora A: Novel 3rd Generation Humanized Type II CD20 Antibody with Glycoengineered Fc and Modified Elbow Hinge for Enhanced ADCC and Superior Apoptosis Induction. ASH Annual Meeting Abstracts. 2006, 108: 229-","journal-title":"ASH Annual Meeting Abstracts"},{"key":"247_CR44","doi-asserted-by":"publisher","first-page":"3762","DOI":"10.4049\/jimmunol.1000303","volume":"186","author":"L Bologna","year":"2011","unstructured":"Bologna L, Gotti E, Manganini M, Rambaldi A, Intermesoli T, Introna M, Golay J: Mechanism of action of type II, glycoengineered, anti-CD20 monoclonal antibody GA101 in B-chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumab. J Immunol. 2011, 186: 3762-3769. 10.4049\/jimmunol.1000303.","journal-title":"J Immunol"},{"key":"247_CR45","first-page":"884","volume":"114","author":"F Morschhauser","year":"2009","unstructured":"Morschhauser F, Cartron G, Lamy T, Milpied N-J, Thieblemont C, Tilly H, Weisser M, Birkett J, Salles GA: Phase I Study of RO5072759 (GA101) in Relapsed\/Refractory Chronic Lymphocytic Leukemia. ASH Annual Meeting Abstracts. 2009, 114: 884-","journal-title":"ASH Annual Meeting Abstracts"},{"key":"247_CR46","doi-asserted-by":"publisher","first-page":"2970","DOI":"10.1182\/blood-2011-04-348896","volume":"118","author":"MQ Lacy","year":"2011","unstructured":"Lacy MQ, Allred JB, Gertz MA, Hayman SR, Short KD, Buadi F, Dispenzieri A, Kumar S, Greipp PR, Lust JA: Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease. Blood. 2011, 118: 2970-2975. 10.1182\/blood-2011-04-348896.","journal-title":"Blood"},{"key":"247_CR47","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1002\/ajh.22233","volume":"87","author":"KH Begna","year":"2012","unstructured":"Begna KH, Pardanani A, Mesa R, Litzow MR, Hogan WJ, Hanson CA, Tefferi A: Long-term outcome of pomalidomide therapy in myelofibrosis. Am J Hematol. 2012, 87: 66-68. 10.1002\/ajh.22233.","journal-title":"Am J Hematol"},{"key":"247_CR48","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/1756-8722-2-36","volume":"2","author":"V Kotla","year":"2009","unstructured":"Kotla V, Goel S, Nischal S, Heuck C, Vivek K, Das B, Verma A: Mechanism of action of lenalidomide in hematological malignancies. J Hematol Oncol. 2009, 2: 36-10.1186\/1756-8722-2-36.","journal-title":"J Hematol Oncol"},{"key":"247_CR49","doi-asserted-by":"publisher","first-page":"3489","DOI":"10.1182\/blood-2011-03-339077","volume":"118","author":"XC Badoux","year":"2011","unstructured":"Badoux XC, Keating MJ, Wen S, Lee BN, Sivina M, Reuben J, Wierda WG, O'Brien SM, Faderl S, Kornblau SM: Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia. Blood. 2011, 118: 3489-3498. 10.1182\/blood-2011-03-339077.","journal-title":"Blood"},{"key":"247_CR50","first-page":"291","volume":"118","author":"DF James","year":"2011","unstructured":"James DF, Brown JR, Werner L, Wierda WG, Barrientos JC, Castro J, Greaves A, Rassenti LZ, Rai KR, Neuberg D, Kipps TJ: Lenalidomide and Rituximab for the Initial Treatment of Patients with Chronic Lymphocytic Leukemia (CLL) A Multicenter Study of the CLL Research Consortium. ASH Annual Meeting Abstracts. 2011, 118: 291-","journal-title":"ASH Annual Meeting Abstracts"},{"key":"247_CR51","first-page":"980","volume":"118","author":"XC Badoux","year":"2011","unstructured":"Badoux XC, Keating MJ, O'Brien S, Wierda WG, Faderl S, Estrov Z, Pasia M, Lerner S, Sargent RL, Kantarjian HM, Ferrajoli A: Final Analysis of a Phase 2 Study of Lenalidomide and Rituximab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL). ASH Annual Meeting Abstracts. 2011, 118: 980-","journal-title":"ASH Annual Meeting Abstracts"},{"key":"247_CR52","first-page":"1788","volume":"118","author":"A Ferrajoli","year":"2011","unstructured":"Ferrajoli A, O'Brien S, Wierda WG, Faderl S, Badoux X, Estrov Z, Schlette E, Smith SC, Ayala AB, Falchi L: Combination Therapy with Ofatumumab and Lenalidomide in Patients with Relapsed Chronic Lymphocytic Leukemia (CLL): Results of a Phase II Trial. ASH Annual Meeting Abstracts. 2011, 118: 1788-","journal-title":"ASH Annual Meeting Abstracts"},{"key":"247_CR53","first-page":"3899","volume":"118","author":"TD Shanafelt","year":"2011","unstructured":"Shanafelt TD, Tun H, Hanson CA, Zent CS, Leis JF, Call TG, LaPlant BR, Bowen D, Pavey ES, Jelinek DF, Kay N: Lenalidomide Consolidation Appears to Prolong Time to Retreatment After First-Line Chemoimmunotherapy for Patients with Previously Untreated CLL. ASH Annual Meeting Abstracts. 2011, 118: 3899-","journal-title":"ASH Annual Meeting Abstracts"},{"key":"247_CR54","first-page":"3907","volume":"118","author":"JV Pozadzides","year":"2011","unstructured":"Pozadzides JV, Keating MJ, Wierda WG, O'Brien S, Burger JA, Jorgensen JL, Calin S, Wang S, Lerner S, Ferrajoli A: Initial Experience with Lenalidomide As Consolidation Treatment in Patients with Chronic Lymphocytic Leukemia and Residual Disease After Chemotherapy. ASH Annual Meeting Abstracts. 2011, 118: 3907-","journal-title":"ASH Annual Meeting Abstracts"},{"key":"247_CR55","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1159\/000204115","volume":"93","author":"AG Bosanquet","year":"1995","unstructured":"Bosanquet AG, McCann SR, Crotty GM, Mills MJ, Catovsky D: Methylprednisolone in advanced chronic lymphocytic leukaemia: rationale for, and effectiveness of treatment suggested by DiSC assay. Acta Haematol. 1995, 93: 73-79. 10.1159\/000204115.","journal-title":"Acta Haematol"},{"key":"247_CR56","doi-asserted-by":"publisher","first-page":"167","DOI":"10.3109\/10428199909083393","volume":"34","author":"PD Thornton","year":"1999","unstructured":"Thornton PD, Hamblin M, Treleaven JG, Matutes E, Lakhani AK, Catovsky D: High dose methyl prednisolone in refractory chronic lymphocytic leukaemia. Leuk Lymphoma. 1999, 34: 167-170.","journal-title":"Leuk Lymphoma"},{"key":"247_CR57","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1007\/s00277-003-0710-5","volume":"82","author":"PD Thornton","year":"2003","unstructured":"Thornton PD, Matutes E, Bosanquet AG, Lakhani AK, Grech H, Ropner JE, Joshi R, Mackie PH, Douglas ID, Bowcock SJ, Catovsky D: High dose methylprednisolone can induce remissions in CLL patients with p53 abnormalities. Ann Hematol. 2003, 82: 759-765. 10.1007\/s00277-003-0710-5.","journal-title":"Ann Hematol"},{"key":"247_CR58","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1038\/leu.2008.214","volume":"22","author":"JE Castro","year":"2008","unstructured":"Castro JE, Sandoval-Sus JD, Bole J, Rassenti L, Kipps TJ: Rituximab in combination with high-dose methylprednisolone for the treatment of fludarabine refractory high-risk chronic lymphocytic leukemia. Leukemia. 2008, 22: 2048-2053. 10.1038\/leu.2008.214.","journal-title":"Leukemia"},{"key":"247_CR59","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1038\/leu.2009.133","volume":"23","author":"JE Castro","year":"2009","unstructured":"Castro JE, James DF, Sandoval-Sus JD, Jain S, Bole J, Rassenti L, Kipps TJ: Rituximab in combination with high-dose methylprednisolone for the treatment of chronic lymphocytic leukemia. Leukemia. 2009, 23: 1779-1789. 10.1038\/leu.2009.133.","journal-title":"Leukemia"},{"key":"247_CR60","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1080\/10428190701724801","volume":"48","author":"DA Bowen","year":"2007","unstructured":"Bowen DA, Call TG, Jenkins GD, Zent CS, Schwager SM, Van Dyke DL, Jelinek DF, Kay NE, Shanafelt TD: Methylprednisolone-rituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavorable cytogenetic features. Leuk Lymphoma. 2007, 48: 2412-2417. 10.1080\/10428190701724801.","journal-title":"Leuk Lymphoma"},{"key":"247_CR61","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.3109\/10428194.2011.562572","volume":"52","author":"R Pileckyte","year":"2011","unstructured":"Pileckyte R, Jurgutis M, Valceckiene V, Stoskus M, Gineikiene E, Sejoniene J, Degulys A, Zvirblis T, Griskevicius L: Dose-dense high-dose methylprednisolone and rituximab in the treatment of relapsed or refractory high-risk chronic lymphocytic leukemia. Leuk Lymphoma. 2011, 52: 1055-1065. 10.3109\/10428194.2011.562572.","journal-title":"Leuk Lymphoma"},{"key":"247_CR62","first-page":"4638","volume":"116","author":"JE Castro","year":"2010","unstructured":"Castro JE, Barajas-Gamboa JS, Melo-Cardenas J, Paz RN, Bernal-Corzo C, Ale-Ali A, James DF, Kipps TJ: Ofatumumab and High-Dose Methylprednisolone Is An Effective Salvage Treatment for Heavily Pretreated, Unfit or Refractory Patients with Chronic Lymphocytic Leukemia: Single Institution Experience. ASH Annual Meeting Abstracts. 2010, 116: 4638-","journal-title":"ASH Annual Meeting Abstracts"},{"key":"247_CR63","doi-asserted-by":"publisher","first-page":"6012","DOI":"10.1200\/JCO.2009.22.6944","volume":"27","author":"TS Lin","year":"2009","unstructured":"Lin TS, Ruppert AS, Johnson AJ, Fischer B, Heerema NA, Andritsos LA, Blum KA, Flynn JM, Jones JA, Hu W: Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease. J Clin Oncol. 2009, 27: 6012-6018. 10.1200\/JCO.2009.22.6944.","journal-title":"J Clin Oncol"},{"key":"247_CR64","first-page":"58","volume":"116","author":"MC Lanasa","year":"2010","unstructured":"Lanasa MC, Andritsos L, Brown JR, Gabrilove J, Caligaris-Cappio F, Larson R, Kipps TJ, Leblond V, Milligan D, Janssens A: Interim Analysis of EFC6663, a Multicenter Phase 2 Study of Alvocidib (flavopiridol), Demonstrates Clinical Responses Among Patients with Fludarabine Refractory CLL. ASH Annual Meeting Abstracts. 2010, 116: 58-","journal-title":"ASH Annual Meeting Abstracts"},{"key":"247_CR65","first-page":"2456","volume":"116","author":"JA Woyach","year":"2010","unstructured":"Woyach JA, Ruppert AS, Blum KA, Jones JA, Flynn JM, Johnson AJ, Grever MR, Byrd JC, Heerema NA: Response, Progression-Free Survival, and Overall Survival of Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Treated with Flavopiridol: Impact of Poor Risk Cytogenetic Abnormalities. ASH Annual Meeting Abstracts. 2010, 116: 2456-","journal-title":"ASH Annual Meeting Abstracts"},{"key":"247_CR66","doi-asserted-by":"publisher","first-page":"423","DOI":"10.3324\/haematol.2011.047324","volume":"97","author":"DM Stephens","year":"2012","unstructured":"Stephens DM, Ruppert AS, Blum K, Jones J, Flynn JM, Johnson AJ, Ji J, Phelps MA, Grever MR, Byrd JC: Flavopiridol treatment of patients aged 70 or older with refractory or relapsed chronic lymphocytic leukemia is a feasible and active therapeutic approach. Haematologica. 2012, 97: 423-427. 10.3324\/haematol.2011.047324.","journal-title":"Haematologica"},{"key":"247_CR67","first-page":"3910","volume":"118","author":"KA Blum","year":"2011","unstructured":"Blum KA, Wei L, Jones JA, Andritsos LA, Flynn JM, Heerema NA, Yang X, Rozewski D, Phelps M, Johnson AJ: Activity of Combined Flavopiridol and Lenalidomide in Patients with Cytogenetically High Risk Chronic Lymphocytic Leukemia (CLL): Updated Results of a Phase I Trial. ASH Annual Meeting Abstracts. 2011, 118: 3910-","journal-title":"ASH Annual Meeting Abstracts"},{"key":"247_CR68","first-page":"1396","volume":"116","author":"JM Flynn","year":"2010","unstructured":"Flynn JM, Jones JA, Andritsos L, Blum KA, Johnson AJ, Hessler J, Wiley E, Poon J, Small K, Statkevich P: Update on the Phase I Study of the Cyclin Dependent Kinase Inhibitor Dinaciclib (SCH 727965) In Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL): Confirmation of Clinical Activity and Feasibility of Long-Term Administration. ASH Annual Meeting Abstracts. 2010, 116: 1396-","journal-title":"ASH Annual Meeting Abstracts"},{"key":"247_CR69","first-page":"883","volume":"114","author":"AW Roberts","year":"2009","unstructured":"Roberts AW, Seymour JF, Brown JR, Wierda WG, Kipps TJ, Carney D, Xiong H, Cui Y, Busman T, Enschede S: An Ongoing Phase 1\/2a Study of ABT-263; Pharmacokinetics (PK), Safety and Anti-Tumor Activity in Patients (pts) with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL). ASH Annual Meeting Abstracts. 2009, 114: 883-","journal-title":"ASH Annual Meeting Abstracts"},{"key":"247_CR70","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1200\/JCO.2011.34.7898","volume":"30","author":"AW Roberts","year":"2012","unstructured":"Roberts AW, Seymour JF, Brown JR, Wierda WG, Kipps TJ, Khaw SL, Carney DA, He SZ, Huang DC, Xiong H: Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol. 2012, 30: 488-496. 10.1200\/JCO.2011.34.7898.","journal-title":"J Clin Oncol"},{"key":"247_CR71","first-page":"3904","volume":"118","author":"TJ Kipps","year":"2011","unstructured":"Kipps TJ, Swinnen LJ, Wierda WG, Jones JA, Coutre SE, Smith MR, Yang J, Cui Y, Busman T, Enschede S, Humerickhouse R: Navitoclax (ABT-263) Plus Fludarabine\/Cyclophosphamide\/Rituximab (FCR) or Bendamustine\/Rituximab (BR): A Phase 1 Study in Patients with Relapsed\/Refractory Chronic Lymphocytic Leukemia (CLL). ASH Annual Meeting Abstracts. 2011, 118: 3904-","journal-title":"ASH Annual Meeting Abstracts"},{"key":"247_CR72","doi-asserted-by":"publisher","first-page":"5208","DOI":"10.1200\/JCO.2009.22.5748","volume":"27","author":"S O'Brien","year":"2009","unstructured":"O'Brien S, Moore JO, Boyd TE, Larratt LM, Skotnicki AB, Koziner B, Chanan-Khan AA, Seymour JF, Gribben J, Itri LM, Rai KR: 5-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersen. J Clin Oncol. 2009, 27: 5208-5212. 10.1200\/JCO.2009.22.5748.","journal-title":"J Clin Oncol"},{"key":"247_CR73","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1182\/blood-2008-02-138560","volume":"113","author":"K Balakrishnan","year":"2009","unstructured":"Balakrishnan K, Burger JA, Wierda WG, Gandhi V: AT-101 induces apoptosis in CLL B cells and overcomes stromal cell-mediated Mcl-1 induction and drug resistance. Blood. 2009, 113: 149-153. 10.1182\/blood-2008-02-138560.","journal-title":"Blood"},{"key":"247_CR74","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1182\/blood-2008-02-137943","volume":"113","author":"SM O'Brien","year":"2009","unstructured":"O'Brien SM, Claxton DF, Crump M, Faderl S, Kipps T, Keating MJ, Viallet J, Cheson BD: Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia. Blood. 2009, 113: 299-305.","journal-title":"Blood"},{"key":"247_CR75","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1038\/leu.2010.322","volume":"25","author":"J Durig","year":"2011","unstructured":"Durig J, Duhrsen U, Klein-Hitpass L, Worm J, Hansen JB, Orum H, Wissenbach M: The novel antisense Bcl-2 inhibitor SPC2996 causes rapid leukemic cell clearance and immune activation in chronic lymphocytic leukemia. Leukemia. 2011, 25: 638-647. 10.1038\/leu.2010.322.","journal-title":"Leukemia"},{"key":"247_CR76","doi-asserted-by":"publisher","first-page":"3603","DOI":"10.1182\/blood-2011-05-352492","volume":"118","author":"J Hoellenriegel","year":"2011","unstructured":"Hoellenriegel J, Meadows SA, Sivina M, Wierda WG, Kantarjian H, Keating MJ, Giese N, O'Brien S, Yu A, Miller LL: The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood. 2011, 118: 3603-3612. 10.1182\/blood-2011-05-352492.","journal-title":"Blood"},{"key":"247_CR77","first-page":"55","volume":"116","author":"RR Furman","year":"2010","unstructured":"Furman RR, Byrd JC, Brown JR, Coutre SE, Benson DM, Wagner-Johnston ND, Flinn IW, Kahl BS, Spurgeon SE, Lannutti B: CAL-101, An Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110{delta}, Demonstrates Clinical Activity and Pharmacodynamic Effects In Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia. ASH Annual Meeting Abstracts. 2010, 116: 55-","journal-title":"ASH Annual Meeting Abstracts"},{"key":"247_CR78","first-page":"1787","volume":"118","author":"J Sharman","year":"2011","unstructured":"Sharman J, de Vos S, Leonard JP, Furman RR, Coutre SE, Flinn IW, Schreeder MT, Barrientos JC, Wagner-Johnston ND, Boyd T: A Phase 1 Study of the Selective Phosphatidylinositol 3-Kinase-Delta (PI3K{delta}) Inhibitor, CAL-101 (GS-1101), in Combination with Rituximab and\/or Bendamustine in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL). ASH Annual Meeting Abstracts. 2011, 118: 1787-","journal-title":"ASH Annual Meeting Abstracts"},{"key":"247_CR79","first-page":"2683","volume":"118","author":"JR Brown","year":"2011","unstructured":"Brown JR, Davids MS, Rodon J, Abrisqueta P, DeCillis AP, Rockich K, Egile C, Kelly A, Xu Y, Lager J, Awan FT: Phase I Trial of SAR245408 (S08), a Pan-Phosphatidylinositol 3 Kinase (PI3K) Inhibitor, in Patients with Chronic Lymphocytic Leukemia (CLL) and Lymphoma. ASH Annual Meeting Abstracts. 2011, 118: 2683-","journal-title":"ASH Annual Meeting Abstracts"},{"key":"247_CR80","doi-asserted-by":"publisher","first-page":"2590","DOI":"10.1182\/blood-2011-11-390989","volume":"119","author":"MF de Rooij","year":"2012","unstructured":"de Rooij MF, Kuil A, Geest CR, Eldering E, Chang BY, Buggy JJ, Pals ST, Spaargaren M: The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood. 2012, 119: 2590-2594. 10.1182\/blood-2011-11-390989.","journal-title":"Blood"},{"key":"247_CR81","first-page":"6508","volume":"29","author":"JC Byrd","year":"2011","unstructured":"Byrd JC, Blum KA, Burger JA, Coutre SE, Sharman JP, Furman RR, Flinn IW, Grant BW, Richards DA, Zhao W: Activity and tolerability of the Bruton's tyrosine kinase (Btk) inhibitor PCI-32765 in patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL): Interim results of a phase Ib\/II study. ASCO Meeting Abstracts. 2011, 29: 6508-","journal-title":"ASCO Meeting Abstracts"},{"key":"247_CR82","first-page":"983","volume":"118","author":"S O'Brien","year":"2011","unstructured":"O'Brien S, Burger JA, Blum KA, Furman RR, Coutre SE, Sharman J, Flinn IW, Grant B, Heerema NA, Johnson AJ: The Bruton's Tyrosine Kinase (BTK) Inhibitor PCI-32765 Induces Durable Responses in Relapsed or Refractory (R\/R) Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma (CLL\/SLL): Follow-up of a Phase Ib\/II Study. ASH Annual Meeting Abstracts. 2011, 118: 983-","journal-title":"ASH Annual Meeting Abstracts"},{"key":"247_CR83","doi-asserted-by":"publisher","first-page":"2578","DOI":"10.1182\/blood-2009-08-236471","volume":"115","author":"JW Friedberg","year":"2010","unstructured":"Friedberg JW, Sharman J, Sweetenham J, Johnston PB, Vose JM, Lacasce A, Schaefer-Cutillo J, De Vos S, Sinha R, Leonard JP: Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood. 2010, 115: 2578-2585. 10.1182\/blood-2009-08-236471.","journal-title":"Blood"},{"key":"247_CR84","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1182\/blood-2009-03-212837","volume":"114","author":"MP Quiroga","year":"2009","unstructured":"Quiroga MP, Balakrishnan K, Kurtova AV, Sivina M, Keating MJ, Wierda WG, Gandhi V, Burger JA: B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406. Blood. 2009, 114: 1029-1037. 10.1182\/blood-2009-03-212837.","journal-title":"Blood"},{"key":"247_CR85","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1038\/leu.2012.24","volume":"26","author":"J Hoellenriegel","year":"2012","unstructured":"Hoellenriegel J, Coffey GP, Sinha U, Pandey A, Sivina M, Ferrajoli A, Ravandi F, Wierda WG, O'Brien S, Keating MJ, Burger JA: Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration. Leukemia. 2012, 26: 1576-1583. 10.1038\/leu.2012.24.","journal-title":"Leukemia"},{"key":"247_CR86","doi-asserted-by":"publisher","first-page":"2977","DOI":"10.1158\/1078-0432.CCR-10-2879","volume":"17","author":"PC Amrein","year":"2011","unstructured":"Amrein PC, Attar EC, Takvorian T, Hochberg EP, Ballen KK, Leahy KM, Fisher DC, Lacasce AS, Jacobsen ED, Armand P: Phase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemia. Clin Cancer Res. 2011, 17: 2977-2986. 10.1158\/1078-0432.CCR-10-2879.","journal-title":"Clin Cancer Res"},{"key":"247_CR87","first-page":"4488","volume":"116","author":"AM Al-Ameri","year":"2010","unstructured":"Al-Ameri AM, Badoux X, Ferrajoli A, Wierda WG, Fayad L, Estrov Z, Bickel S, Keating MJ, O'Brien S: Phase II Study of Dasatinib In Patients with Relapsed Chronic Lymphocytic Leukemia. ASH Annual Meeting Abstracts. 2010, 116: 4488-","journal-title":"ASH Annual Meeting Abstracts"},{"key":"247_CR88","first-page":"2858","volume":"118","author":"T Kadia","year":"2011","unstructured":"Kadia T, Delioukina ML, Kantarjian HM, Keating MJ, Wierda WG, Burger JA, Wieland S, Levitt D: A Pilot Phase II Study of the Lyn Kinase Inhibitor Bafetinib in Patients with Relapsed or Refractory B Cell Chronic Lymphocytic Leukemia. ASH Annual Meeting Abstracts. 2011, 118: 2858-","journal-title":"ASH Annual Meeting Abstracts"},{"key":"247_CR89","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1182\/blood-2010-09-308775","volume":"117","author":"M Michallet","year":"2011","unstructured":"Michallet M, Dreger P, Sutton L, Brand R, Richards S, van Os M, Sobh M, Choquet S, Corront B, Dearden C: Autologous hematopoietic stem cell transplantation in chronic lymphocytic leukemia: results of European intergroup randomized trial comparing autografting versus observation. Blood. 2011, 117: 1516-1521. 10.1182\/blood-2010-09-308775.","journal-title":"Blood"},{"key":"247_CR90","doi-asserted-by":"publisher","first-page":"4851","DOI":"10.1182\/blood-2011-09-378505","volume":"119","author":"P Dreger","year":"2012","unstructured":"Dreger P, Dohner H, McClanahan F, Busch R, Ritgen M, Greinix H, Fink AM, Knauf W, Stadler M, Pfreundschuh M: Early autologous stem cell transplantation for chronic lymphocytic leukemia: long-term follow-up of the German CLL Study Group CLL3 trial. Blood. 2012, 119: 4851-4859. 10.1182\/blood-2011-09-378505.","journal-title":"Blood"},{"key":"247_CR91","doi-asserted-by":"publisher","first-page":"7757","DOI":"10.1158\/1078-0432.CCR-05-0941","volume":"11","author":"D Caballero","year":"2005","unstructured":"Caballero D, Garcia-Marco JA, Martino R, Mateos V, Ribera JM, Sarra J, Leon A, Sanz G, de la Serna J, Cabrera R: Allogeneic transplant with reduced intensity conditioning regimens may overcome the poor prognosis of B-cell chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene and chromosomal abnormalities (11q- and 17p-). Clin Cancer Res. 2005, 11: 7757-7763. 10.1158\/1078-0432.CCR-05-0941.","journal-title":"Clin Cancer Res"},{"key":"247_CR92","doi-asserted-by":"publisher","first-page":"3433","DOI":"10.1200\/JCO.2005.04.531","volume":"23","author":"C Moreno","year":"2005","unstructured":"Moreno C, Villamor N, Colomer D, Esteve J, Martino R, Nomdedeu J, Bosch F, Lopez-Guillermo A, Campo E, Sierra J, Montserrat E: Allogeneic stem-cell transplantation may overcome the adverse prognosis of unmutated VH gene in patients with chronic lymphocytic leukemia. J Clin Oncol. 2005, 23: 3433-3438. 10.1200\/JCO.2005.04.531.","journal-title":"J Clin Oncol"},{"key":"247_CR93","doi-asserted-by":"publisher","first-page":"5788","DOI":"10.1200\/JCO.2005.03.962","volume":"23","author":"SZ Pavletic","year":"2005","unstructured":"Pavletic SZ, Khouri IF, Haagenson M, King RJ, Bierman PJ, Bishop MR, Carston M, Giralt S, Molina A, Copelan EA: Unrelated donor marrow transplantation for B-cell chronic lymphocytic leukemia after using myeloablative conditioning: results from the Center for International Blood and Marrow Transplant research. J Clin Oncol. 2005, 23: 5788-5794. 10.1200\/JCO.2005.03.962.","journal-title":"J Clin Oncol"},{"key":"247_CR94","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/sj.bmt.1702237","volume":"25","author":"ZS Pavletic","year":"2000","unstructured":"Pavletic ZS, Arrowsmith ER, Bierman PJ, Goodman SA, Vose JM, Tarantolo SR, Stein RS, Bociek G, Greer JP, Wu CD: Outcome of allogeneic stem cell transplantation for B cell chronic lymphocytic leukemia. Bone Marrow Transplant. 2000, 25: 717-722. 10.1038\/sj.bmt.1702237.","journal-title":"Bone Marrow Transplant"},{"key":"247_CR95","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1182\/asheducation-2009.1.602","volume":"1","author":"P Dreger","year":"2009","unstructured":"Dreger P: Allotransplantation for chronic lymphocytic leukemia. Hematology \/ the Education Program of the American Society of Hematology American Society of Hematology Education Program. 2009, 1: 602-609.","journal-title":"Hematology \/ the Education Program of the American Society of Hematology American Society of Hematology Education Program"},{"key":"247_CR96","doi-asserted-by":"publisher","first-page":"2581","DOI":"10.1182\/blood-2009-05-206821","volume":"114","author":"J Delgado","year":"2009","unstructured":"Delgado J, Milligan DW, Dreger P: Allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia: ready for prime time?. Blood. 2009, 114: 2581-2588. 10.1182\/blood-2009-05-206821.","journal-title":"Blood"},{"key":"247_CR97","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1177\/107327481201900107","volume":"19","author":"MA Kharfan-Dabaja","year":"2012","unstructured":"Kharfan-Dabaja MA, Bazarbachi A: Hematopoietic stem cell allografting for chronic lymphocytic leukemia: a focus on reduced-intensity conditioning regimens. Cancer control: journal of the Moffitt Cancer Center. 2012, 19: 68-75.","journal-title":"Cancer control: journal of the Moffitt Cancer Center"},{"key":"247_CR98","first-page":"4123","volume":"118","author":"Y Hsu","year":"2011","unstructured":"Hsu Y, Saliba RM, Okoroji G-J, o'Brien S, Ferrajoli A, Abruzzo LV, Champlin R, Keating MJ, Khouri IF: Feasibility Analysis of Nonmyeloabltive Allogeneic Stem Cell Transplantation (NST) in Patients with Chronic Lymphocytic Leukemia (CLL) and 17p- Deletion. ASH Annual Meeting Abstracts. 2011, 118: 4123-","journal-title":"ASH Annual Meeting Abstracts"},{"key":"247_CR99","first-page":"200","volume":"11","author":"C Milani","year":"2009","unstructured":"Milani C, Castillo J: Veltuzumab, an anti-CD20 mAb for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and immune thrombocytopenic purpura. Curr Opin Mol Ther. 2009, 11: 200-207.","journal-title":"Curr Opin Mol Ther"},{"key":"247_CR100","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1158\/1078-0432.CCR-11-0850","volume":"18","author":"A Forero-Torres","year":"2012","unstructured":"Forero-Torres A, de Vos S, Pohlman BL, Pashkevich M, Cronier DM, Dang NH, Carpenter SP, Allan BW, Nelson JG, Slapak CA: Results of a phase 1 study of AME-133v (LY2469298), an Fc-engineered humanized monoclonal anti-CD20 antibody, in FcgammaRIIIa-genotyped patients with previously treated follicular lymphoma. Clin Cancer Res. 2012, 18: 1395-1403. 10.1158\/1078-0432.CCR-11-0850.","journal-title":"Clin Cancer Res"},{"key":"247_CR101","first-page":"1683","volume":"38","author":"S Baritaki","year":"2011","unstructured":"Baritaki S, Militello L, Malaponte G, Spandidos DA, Salcedo M, Bonavida B: The anti-CD20 mAb LFB-R603 interrupts the dysregulated NF-kappaB\/Snail\/RKIP\/PTEN resistance loop in B-NHL cells: role in sensitization to TRAIL apoptosis. Int J Oncol. 2011, 38: 1683-1694.","journal-title":"Int J Oncol"},{"key":"247_CR102","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.1158\/1078-0432.CCR-08-1694","volume":"15","author":"MS Hayden-Ledbetter","year":"2009","unstructured":"Hayden-Ledbetter MS, Cerveny CG, Espling E, Brady WA, Grosmaire LS, Tan P, Bader R, Slater S, Nilsson CA, Barone DS: CD20-directed small modular immunopharmaceutical, TRU-015, depletes normal and malignant B cells. Clin Cancer Res. 2009, 15: 2739-2746. 10.1158\/1078-0432.CCR-08-1694.","journal-title":"Clin Cancer Res"},{"key":"247_CR103","first-page":"1383","volume":"10","author":"T Robak","year":"2009","unstructured":"Robak T, Robak P, Smolewski P: TRU-016, a humanized anti-CD37 IgG fusion protein for the potential treatment of B-cell malignancies. Curr Opin Investig Drugs. 2009, 10: 1383-1390.","journal-title":"Curr Opin Investig Drugs"},{"key":"247_CR104","doi-asserted-by":"publisher","first-page":"228","DOI":"10.3109\/10428190903440946","volume":"51","author":"RR Furman","year":"2010","unstructured":"Furman RR, Forero-Torres A, Shustov A, Drachman JG: A phase I study of dacetuzumab (SGN-40, a humanized anti-CD40 monoclonal antibody) in patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2010, 51: 228-235. 10.3109\/10428190903440946.","journal-title":"Leuk Lymphoma"},{"key":"247_CR105","volume-title":"Leuk Lymphoma","author":"JC Byrd","year":"2012","unstructured":"Byrd JC, Kipps TJ, Flinn IW, Cooper M, Odenike O, Bendiske J, Rediske J, Bilic S, Dey J, Baeck J, O'Brien S: Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia. Leuk Lymphoma. 2012, in press"},{"key":"247_CR106","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.3109\/10428194.2011.647310","volume":"53","author":"OG Best","year":"2012","unstructured":"Best OG, Che Y, Singh N, Forsyth C, Christopherson RI, Mulligan SP: The Hsp90 inhibitor SNX-7081 synergizes with and restores sensitivity to fludarabine in chronic lymphocytic leukemia cells with lesions in the TP53 pathway: a potential treatment strategy for fludarabine refractory disease. Leuk Lymphoma. 2012, 53: 1367-1375. 10.3109\/10428194.2011.647310.","journal-title":"Leuk Lymphoma"},{"key":"247_CR107","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1182\/blood-2010-01-263756","volume":"116","author":"E Hertlein","year":"2010","unstructured":"Hertlein E, Wagner AJ, Jones J, Lin TS, Maddocks KJ, Towns WH, Goettl VM, Zhang X, Jarjoura D, Raymond CA: 17-DMAG targets the nuclear factor-kappaB family of proteins to induce apoptosis in chronic lymphocytic leukemia: clinical implications of HSP90 inhibition. Blood. 2010, 116: 45-53. 10.1182\/blood-2010-01-263756.","journal-title":"Blood"},{"key":"247_CR108","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/1756-8722-3-5","volume":"3","author":"J Tan","year":"2010","unstructured":"Tan J, Cang S, Ma Y, Petrillo RL, Liu D: Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. J Hematol Oncol. 2010, 3: 5-10.1186\/1756-8722-3-5.","journal-title":"J Hematol Oncol"},{"key":"247_CR109","doi-asserted-by":"publisher","first-page":"218","DOI":"10.3109\/10428194.2011.610012","volume":"53","author":"MC Lanasa","year":"2012","unstructured":"Lanasa MC, Davis PH, Datto M, Li Z, Gockerman JP, Moore JO, Decastro CM, Friedman DR, Diehl LF, Rehder C: Phase II study of cenersen, an antisense inhibitor of p53, in combination with fludarabine, cyclophosphamide and rituximab for high-risk chronic lymphocytic leukemia. Leuk Lymphoma. 2012, 53: 218-224. 10.3109\/10428194.2011.610012.","journal-title":"Leuk Lymphoma"},{"key":"247_CR110","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1756-8722-4-16","volume":"4","author":"Y Yuan","year":"2011","unstructured":"Yuan Y, Liao YM, Hsueh CT, Mirshahidi HR: Novel targeted therapeutics: inhibitors of MDM2. ALK and PARP. Journal of hematology & oncology. 2011, 4: 16-10.1186\/1756-8722-4-16.","journal-title":"Journal of hematology & oncology"},{"key":"247_CR111","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s00277-008-0582-9","volume":"88","author":"T Decker","year":"2009","unstructured":"Decker T, Sandherr M, Goetze K, Oelsner M, Ringshausen I, Peschel C: A pilot trial of the mTOR (mammalian target of rapamycin) inhibitor RAD001 in patients with advanced B-CLL. Ann Hematol. 2009, 88: 221-227. 10.1007\/s00277-008-0582-9.","journal-title":"Ann Hematol"}],"container-title":["Journal of Hematology & Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1756-8722-5-55.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1756-8722-5-55\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1756-8722-5-55.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T12:44:07Z","timestamp":1714394647000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/1756-8722-5-55"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9,16]]},"references-count":111,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["247"],"URL":"https:\/\/doi.org\/10.1186\/1756-8722-5-55","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,9,16]]},"article-number":"55"}}